The stock of Allogene Therapeutics Inc. (NASDAQ:ALLO) last traded at $4.58, down -1.08% from the previous session.
Data from the available sources indicates that Allogene Therapeutics Inc. (NASDAQ:ALLO) is covered by 19 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $35.00 and a low of $6.00, we find $15.00. Given the previous closing price of $4.63, this indicates a potential upside of 223.97 percent. ALLO stock price is now -17.43% away from the 50-day moving average and -38.57% away from the 200-day moving average. The market capitalization of the company currently stands at $669.37M.
In total, 3 analysts have assigned it a hold rating, and 14 have given it a buy rating. Brokers who have rated the stock have averaged $16.91 as their price target over the next twelve months.
In other news, Bhavnagri Veer, General Counsel sold 3,000 shares of the company’s stock on Feb 13. The stock was sold for $20,550 at an average price of $6.85. Upon completion of the transaction, the General Counsel now directly owns 577,677 shares in the company, valued at $2.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 17, General Counsel Bhavnagri Veer sold 3,000 shares of the business’s stock. A total of $21,120 was realized by selling the stock at an average price of $7.04. This leaves the insider owning 580,677 shares of the company worth $2.66 million. Insiders disposed of 153,232 shares of company stock worth roughly $0.7 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ALLO stock. A new stake in Allogene Therapeutics Inc. shares was purchased by BAKER BROS. ADVISORS LP during the first quarter worth $7,222,000. UBS ASSET MANAGEMENT AMERICAS INC invested $2,442,000 in shares of ALLO during the first quarter. In the first quarter, MARSHALL WACE, LLP acquired a new stake in Allogene Therapeutics Inc. valued at approximately $1,992,000. INTEGRAL HEALTH ASSET MANAGEMENT, LLC acquired a new stake in ALLO for approximately $1,855,000. JEFFERIES FINANCIAL GROUP INC. purchased a new stake in ALLO valued at around $1,814,000 in the second quarter. In total, there are 259 active investors with 76.20% ownership of the company’s stock.
With an opening price of $4.6200 on Thursday morning, Allogene Therapeutics Inc. (NASDAQ: ALLO) set off the trading day. During the past 12 months, Allogene Therapeutics Inc. has had a low of $4.30 and a high of $17.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.10, and a quick ratio of 8.10. The fifty day moving average price for ALLO is $5.5472 and a two-hundred day moving average price translates $7.4558 for the stock.
The latest earnings results from Allogene Therapeutics Inc. (NASDAQ: ALLO) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.68, missing analysts’ expectations of -$0.62 by -0.06. This compares to -$0.56 EPS in the same period last year. The company reported revenue of $52000.0 for the quarter, compared to $61000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -14.75 percent. For the current quarter, analysts expect ALLO to generate $20k in revenue.
Allogene Therapeutics Inc.(ALLO) Company Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
